全文获取类型
收费全文 | 768篇 |
免费 | 102篇 |
国内免费 | 128篇 |
专业分类
化学 | 700篇 |
力学 | 26篇 |
综合类 | 23篇 |
数学 | 55篇 |
物理学 | 194篇 |
出版年
2024年 | 2篇 |
2023年 | 20篇 |
2022年 | 34篇 |
2021年 | 97篇 |
2020年 | 75篇 |
2019年 | 48篇 |
2018年 | 30篇 |
2017年 | 36篇 |
2016年 | 47篇 |
2015年 | 42篇 |
2014年 | 55篇 |
2013年 | 70篇 |
2012年 | 54篇 |
2011年 | 45篇 |
2010年 | 41篇 |
2009年 | 35篇 |
2008年 | 39篇 |
2007年 | 31篇 |
2006年 | 27篇 |
2005年 | 31篇 |
2004年 | 24篇 |
2003年 | 15篇 |
2002年 | 21篇 |
2001年 | 12篇 |
2000年 | 10篇 |
1999年 | 4篇 |
1998年 | 12篇 |
1997年 | 8篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 4篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 3篇 |
1971年 | 1篇 |
排序方式: 共有998条查询结果,搜索用时 78 毫秒
61.
Fanchen Jing Guiliang Li Yingsa Wang Shangbin Zhu Rundong Liu Jing He Jiandu Lei 《先进技术聚合物》2021,32(1):343-354
Carboxymethyl chitosan (CMCS), as a water‐soluble, biocompatible, and biodegradable polymer, is an excellent carrier for a sustained drug delivery system. In this study, a amphiphilic carboxymethyl chitosan‐ursolic acid nano‐drug carrier modified by folic acid (FPCU) were prepared, and then the nano‐drug carrier wrapped another anticancer drug 10‐hydroxycamptothecin were self‐assembled into nanoparticles (FPCU/HCPT NPs). The FPCU/HCPT NPs had a suitable size, high drug loading efficiency of ursolic acid (6.4%) and 10‐hydroxycamptothecin (14.1%). The drug release study in vitro indicated that the nanoparticles have obviously sustained effect and pH sensitive behaviors, the drug release amount was higher at pH 5.5 than at pH 7.4. in vitro and in vivo study showed that the nanoparticles displayed a high antitumor efficiency to tumor cells compared with free drug. The nano delivery system as a carrier for ursolic acid (UA) and 10‐hydroxycamptothecin (HCPT) has good application prospects in cancer treatment. 相似文献
62.
63.
基于罗丹明的良好荧光性能, 经化学偶联反应制备并表征了一个偶氮乏氧特异响应的“Off-On”型荧光成像探针(FY-4). 从分子层面证实了其荧光“Off-On”性能和响应机制; 在L02正常细胞及4T1, HeLa和A549肿瘤细胞层面考察了其对受试细胞株的毒性和不同乏氧时间的荧光成像性能; 再利用4T1肿瘤模型, 分别以肿瘤原位注射和尾静脉注射的方式考察了其荧光成像性能, 并探究了其荧光成像介导切除肿瘤性能, 最后还考察了FY-4的生物安全性. 结果表明, FY-4有高的肿瘤乏氧靶向特异“关-开”响应的荧光成像差异显影及荧光成像介导切除肿瘤的潜能, 结合其良好的光物理性能、 生物安全性和明晰的给药时间等特性, 有望为生物医学荧光成像介导肿瘤切除提供新的研究工具. 相似文献
64.
基于透明质酸构筑的药物递送载体及其应用 总被引:1,自引:0,他引:1
传统纳米药物控释载体主要通过细胞胞吞作用实现药物递送,其主要过程为被动靶向机制,因此会影响纳米载体在肿瘤组织的富集和治疗效果。近年来生物大分子透明质酸因其优异的水溶性、生物相容性、可降解性和肿瘤靶向性备受科研工作者青睐,已被广泛用于药物控释载体的构筑中,并成为靶向肿瘤治疗纳米载体领域的研究热点。本文根据透明质酸基纳米载体治疗机制的不同,从透明质酸基纳米载体在化疗、光热治疗、光动力治疗以及联合治疗的应用方面对其性能进行了总结和评述,并在此基础上展望了未来透明质酸基纳米治疗载体的研究方向和发展趋势。 相似文献
65.
以聚乙烯亚胺(PEI)修饰的多壁碳纳米管(PEI-CNT)为模板,利用异硫氰酸荧光素(FITC)和乳糖酸(LA)对其表面进行修饰,合成乳糖酸修饰的PEI-CNT复合载体,并负载抗肿瘤药物盐酸阿霉素(DOX),使其成为具有靶向功能的新型抗肿瘤药物载体。采用核磁共振(1 HNMR)、透射电镜、共聚焦显微镜及流式细胞仪等测试手段分析载体的结构和性质。载药复合体系在酸性条件下的体外药物释放速率明显高于中性条件下的,同时该复合载药体系对肝癌细胞(SMMC-7721)具有一定的靶向性。 相似文献
66.
HPLC‐MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E‐3810 in tumor tissues from xenograft mice and human biopsies 下载免费PDF全文
Monique Zangarini Laura Ceriani Ezia Bello Giovanna Damia Roberta Cereda Maria Gabriella Camboni Massimo Zucchetti 《Journal of mass spectrometry : JMS》2014,49(1):19-26
We developed and validated a high‐performance liquid chromatography–tandem mass spectrometry analytical method to measure E‐3810, a novel dual inhibitor of fibroblast growth factor receptor 1 and vascular endothelial growth factor receptor 1–3 in tissues and determined the drug concentration in a biopsy of human breast cancer for the first time. The method is a modification of our previous one in plasma to study the clinical pharmacokinetics of the drug during the phase I/II trial. In view of the changes in matrix, we applied a partial validation protocol to determine recovery, sensitivity, range of linearity, precision, accuracy and stability of the method over three runs in a mouse tumor tissue and liver. The recovery of E‐3810 from liver or tumor homogenate was >69%, and the lower limit of quantification was 5 ng/ml. The method was linear in the concentration range 5.0–500.0 ng/ml, as demonstrated by a determination coefficient R2 ≥ 0.9955. The range of the calibration curve was appropriate for the analysis, as demonstrated by the accuracy, which was between 91.4% and 106.7%. Interday precision and accuracy on quality control samples at 9, 30 and 300 ng/ml were 3.1‐11.2% and 98.3–111.4%, respectively. The assay was applied successfully to determine the intratumor concentration of E‐3810 in different mouse xenograft tumor models and in a biopsy of a patient with breast cancer included in the phase I/II trial of the drug. In mouse tumors, the concentrations of E‐3810 were higher than necessary to exert antitumor activity in vitro (1 µM). Even more of interest was the result obtained in a human biopsy of few milligrams, where E‐3810 reached 4.9 µg/g (11 µM). Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
67.
Immuno‐Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents 下载免费PDF全文
Daniel Yuan Qiang Wong Charmian Hui Fang Yeo Prof. Wee Han Ang 《Angewandte Chemie (International ed. in English)》2014,53(26):6752-6756
There is growing consensus that the clinical therapeutic efficacy of some chemotherapeutic agents depends on their off‐target immune‐modulating effects. Pt anticancer drugs have previously been identified to be potent immunomodulators of both the innate and the adaptive immune system. Nevertheless, there has been little development in the rational design of Pt‐based chemotherapeutic agents to exploit their immune‐activating capabilities. The FPR1/2 formyl peptide receptors are highly expressed in immune cells, as well as in many metastatic cancers. Herein, we report a rationally designed multimodal PtIV prodrug containing a FPR1/2‐targeting peptide that combines chemotherapy with immunotherapy to achieve therapeutic synergy and demonstrate the feasibility of this approach. 相似文献
68.
Protein kinase C (PKC) isozymes play central roles in signal transduction on the cell surface and could serve as promising therapeutic targets of intractable diseases like cancer, Alzheimer's disease, and acquired immunodeficiency syndrome (AIDS). Although natural PKC ligands like phorbol esters, ingenol esters, and teleocidins have the potential to become therapeutic leads, most of them are potent tumor promoters in mouse skin. By contrast, bryostatin‐1 (bryo‐1) isolated from marine bryozoan is a potent PKC activator with little tumor‐promoting activity. Numerous investigations have suggested bryo‐1 to be a promising therapeutic candidate for the above intractable diseases. However, there is a supply problem of bryo‐1 both from natural sources and by organic synthesis. Recent approaches on the synthesis of bryo‐1 have focused on its simplification, without decreasing the ability to activate PKC isozymes, to develop new medicinal leads. Another approach is to use the skeleton of natural PKC ligands to develop bryo‐1 surrogates. We have recently identified 10‐methyl‐aplog‐1 ( 26 ), a simplified analog of tumor‐promoting aplysiatoxin (ATX), as a possible therapeutic lead for cancer. This review summarizes recent investigations on the simplification of natural PKC ligands, bryo‐1 and ATX, to develop potential medicinal leads. 相似文献
69.
Dr. Deng Pan Zhengzou Fang Erli Yang Zhenqiang Ning Qing Zhou Kaiyang Chen Yongjun Zheng Prof. Yuanjian Zhang Prof. Yanfei Shen 《Angewandte Chemie (Weinheim an der Bergstrasse, Germany)》2020,132(38):16890-16897
The exceptional nature of WO3−x dots has inspired widespread interest, but it is still a significant challenge to synthesize high-quality WO3−x dots without using unstable reactants, expensive equipment, and complex synthetic processes. Herein, the synthesis of ligand-free WO3−x dots is reported that are highly dispersible and rich in oxygen vacancies by a simple but straightforward exfoliation of bulk WS2 and a mild follow-up chemical conversion. Surprisingly, the WO3−x dots emerged as co-reactants for the electrochemiluminescence (ECL) of Ru(bpy)32+ with a comparable ECL efficiency to the well-known Ru(bpy)32+/tripropylamine (TPrA) system. Moreover, compared to TPrA, whose toxicity remains a critical issue of concern, the WO3−x dots were ca. 300-fold less toxic. The potency of WO3−x dots was further explored in the detection of circulating tumor cells (CTCs) with the most competitive limit of detection so far. 相似文献
70.
Dr. Shan Sun Qiao Chen Zhongdi Tang Chuang Liu Prof. Zhongjun Li Prof. Aiguo Wu Prof. Hengwei Lin 《Angewandte Chemie (Weinheim an der Bergstrasse, Germany)》2020,132(47):21227-21234
A method is developed to fabricate tumor microenvironment (TME) stimuli-responsive nanoplatform for fluorescence (FL) imaging and synergistic cancer therapy via assembling photosensitizer (chlorine e6, Ce6) modified carbon dots (CDs-Ce6) and Cu2+. The as-obtained nanoassemblies (named Cu/CC nanoparticles, NPs) exhibit quenched FL and photosensitization due to the aggregation of CDs-Ce6. Their FL imaging and photodynamic therapy (PDT) functions are recovered efficiently once they entering tumor sites by the stimulation of TME. Introducing of Cu2+ not only provides extra chemodynamic therapy (CDT) function through reaction with hydrogen peroxide (H2O2), but also depletes GSH in tumors by a redox reaction, thus amplifying the intracellular oxidative stress and enhancing the efficacy of reactive oxygen species (ROS) based therapy. Cu/CC NPs can act as a FL imaging guided trimodal synergistic cancer treatment agent by photothermal therapy (PTT), PDT, and thermally amplified CDT. 相似文献